biotech

Abivax CEO dismisses acquisition rumors, plans equity and debt raise after Phase 3 obefazimod data in Q2 2026. $614.42M cash runway supports strategy.

iDEL Therapeutics appoints Dr. Claudia Ulbrich as Board Chair and secures €9M seed funding led by BiomedVC to advance its novel cancer drug delivery platform.

Sarissa Capital deploys $5.79M in beaten-down biotech Biohaven despite 70% stock decline, betting on upcoming late-stage trial data and obesity candidate.

Molecular Partners nominates M&A veteran Clare Fisher to its board as 12-year member Steven Holtzman retires, signaling strategic emphasis on business development and partnerships.

ARK Invest bought just three stocks last week—Figma, Arcturus Therapeutics, and 10x Genomics—signaling selective conviction in growth equities amid broader market uncertainty.

Boone Capital liquidates entire $13.57M Cogent Biosciences stake despite 372% gain, reallocating to earlier-stage biotech plays like TYRA. Strategic rebalancing in volatile sector.

Abivax and Nektar Therapeutics are positioned as acquisition targets with promising drug candidates and upcoming phase 3 trial data, attracting interest from major pharmaceutical companies.

Healthcare sector faces pullback amid Middle East tensions, but dividend-paying stocks and funds offer yields of 6-14.1% with varying risk profiles.

Moderna's 69% YTD gain reflects mRNA vaccine upside, while Pfizer's 6.3% dividend offers stability as COVID revenues fade. Choice depends on risk appetite.

Institutional investors rotate capital to precision oncology biotech as patent cliff pressures Big Pharma. Five clinical-stage companies positioned for M&A amid $303B market opportunity.

Soligenix's HyBryte study shows 48% response rate, nearly double the 25% threshold, with interim results expected this quarter.

Ovid Therapeutics surges 18% after Phase 1 data shows OV329 epilepsy drug eliminated safety concerns. Company secures $60M to fund Phase 2 trials.

Three healthcare stocks under $50 offer distinct value: Pfizer at $27.45 with 9x P/E and strong oncology pipeline; Novo Nordisk at $38.43 capitalizing on weight-loss drugs; Exelixis at $41.80 with proven oncology franchise.

JPMorgan raises Edgewise Therapeutics price target to $45, citing positive long-term clinical data for EDG-7500 and sevasemten. Stock rises 2.18%.

Rhythm Pharmaceuticals' setmelanotide fails EMANATE Phase 3 primary endpoints for rare genetic obesity, sending stock down 4.98%. Company pivots to next-generation MC4R agonists.

Edgewise Therapeutics pursues two major drug candidates addressing unmet cardiac and muscular disease needs, with pivotal data expected through 2026.

Vestal Point Capital sold $103.93M in Nuvalent shares, reducing exposure despite company's 30% rally and $1.4B cash position awaiting 2026 FDA decisions.

Cormorant Asset Management sold $PRAX shares for $9.3M in Q4, yet position surged $227M in value. Stock remains fund's largest holding at $280M.

$COGT surges 5.24% after FDA accepts bezuclastinib NDA for Non-Advanced Systemic Mastocytosis, with decision expected by December 2026.

Vertex Pharmaceuticals eyes 25% stock upside to $600 as it expands beyond cystic fibrosis with new drug approvals and kidney disease candidate povetacicept.